DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

NCT03523585 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

608

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Capecitabine
DRUG: Lapatinib
DRUG: Trastuzumab

Sponsor

Daiichi Sankyo

Collaborators

[object Object]
[object Object]